title: Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine.
abstract: BACKGROUND
  Sulfadoxine-pyrimethamine was a common first line drug therapy to treat uncomplicated falciparum malaria, but increasing therapeutic failures associated with the development of significant levels of resistance worldwide has prompted change to alternative treatment regimes in many national malaria control programs. METHODOLOGY AND FINDING: We conducted an in vivo therapeutic efficacy trial of sulfadoxine-pyrimethamine at two locations in the Peruvian Amazon enrolling 99 patients of which, 86 patients completed the protocol specified 28 day follow up. Our objective was to correlate the presence of polymorphisms in P. falciparum dihydrofolate reductase and dihydropteroate synthase to in vitro parasite susceptibility to sulfadoxine and pyrimethamine and to in vivo treatment outcomes. Inhibitory concentration 50 values of isolates increased with numbers of mutations (single [108N], sextuplet [BR/51I/108N/164L and 437G/581G]) and septuplet (BR/51I/108N/164L and 437G/540E/581G) with geometric means of 76 nM (35-166 nM), 582 nM (49-6890- nM) and 4909 (3575-6741 nM) nM for sulfadoxine and 33 nM (22-51 nM), 81 nM (19-345 nM), and 215 nM (176-262 nM) for pyrimethamine. A single mutation present in the isolate obtained at the time of enrollment from either dihydrofolate reductase (164L) or dihydropteroate synthase (540E) predicted treatment failure as well as any other single gene alone or in combination. Patients with the dihydrofolate reductase 164L mutation were 3.6 times as likely to be treatment failures [failures 85.4% (164L) vs 23.7% (I164); relative risk = 3.61; 95% CI: 2.14 - 6.64] while patients with the dihydropteroate synthase 540E were 2.6 times as likely to fail treatment (96.7% (540E) vs 37.5% (K540); relative risk = 2.58; 95% CI: 1.88 - 3.73). Patients with both dihydrofolate reductase 164L and dihydropteroate synthase 540E mutations were 4.1 times as likely to be treatment failures [96.7% vs 23.7%; RR = 4.08; 95% CI: 2.45 - 7.46] compared to patients having both wild forms (I164 and K540).
  
  
  CONCLUSIONS
  In this part of the Amazon basin, it may be possible to predict treatment failure with sulfadoxine-pyrimethamine equally well by determination of either of the single mutations dihydrofolate reductase 164L or dihydropteroate synthase 540E.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT00951106.
authors.affiliation: Parasitology Program, Naval Medical Research Center Detachment, Lima, Peru. david.bacon@med.navy.mil
authors.forename: David J
authors.initials: DJ
authors.lastname: Bacon
authors.forename: Doug
authors.initials: D
authors.lastname: Tang
authors.forename: Carola
authors.initials: C
authors.lastname: Salas
authors.forename: Norma
authors.initials: N
authors.lastname: Roncal
authors.forename: Carmen
authors.initials: C
authors.lastname: Lucas
authors.forename: Lucia
authors.initials: L
authors.lastname: Gerena
authors.forename: Lorena
authors.initials: L
authors.lastname: Tapia
authors.forename: A Alejandro
authors.initials: AA
authors.lastname: Llanos-Cuentas
authors.forename: Coralith
authors.initials: C
authors.lastname: Garcia
authors.forename: Lelv
authors.initials: L
authors.lastname: Solari
authors.forename: Dennis
authors.initials: D
authors.lastname: Kyle
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Magill
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D004094:Dihydropteroate Synthase / Q000235:genetics*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000201:enzymology*; D017354:Point Mutation; D011739:Pyrimethamine / Q000494:pharmacology*; D013413:Sulfadoxine / Q000494:pharmacology*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics*
chemical_list: D000962:Antimalarials; D013413:Sulfadoxine; D013762:Tetrahydrofolate Dehydrogenase; D004094:Dihydropteroate Synthase; D011739:Pyrimethamine
references.citation: Lancet. 1987 Dec 5;2(8571):1304-5
references.pmid: 2890904
references.citation: J Infect Dis. 1997 Dec;176(6):1590-6
references.pmid: 9395372
references.citation: Malar J. 2008 May 27;7:93
references.pmid: 18505558
references.citation: Mol Biochem Parasitol. 2004 Jul;136(1):63-70
references.pmid: 15138068
references.citation: Am J Trop Med Hyg. 2007 Apr;76(4):614-8
references.pmid: 17426158
references.citation: Malar J. 2007 Nov 16;6:153
references.pmid: 18021388
references.citation: Malar J. 2006 Oct 31;5:94
references.pmid: 17076899
references.citation: J Chromatogr B Biomed Sci Appl. 1999 Apr 30;727(1-2):159-65
references.pmid: 10360435
references.citation: Nature. 1978 Jun 22;273(5664):621-2
references.pmid: 351412
references.citation: Antimicrob Agents Chemother. 1979 Dec;16(6):710-8
references.pmid: 394674
references.citation: World Health Organ Tech Rep Ser. 1973;529:1-121
references.pmid: 4200089
references.citation: Acta Trop. 2005 Sep;95(3):172-82
references.pmid: 16018959
references.citation: AIDS. 1999 Mar 11;13(4):487-94
references.pmid: 10197377
references.citation: PLoS Clin Trials. 2006 Jul 21;1(3):e15
references.pmid: 16871318
references.citation: PLoS Clin Trials. 2006 Jul 21;1(3):e14
references.pmid: 16871319
references.citation: Ann Trop Med Parasitol. 2007 Mar;101(2):103-12
references.pmid: 17316496
references.citation: Fundam Clin Pharmacol. 2003 Apr;17(2):147-53
references.pmid: 12667224
references.citation: Am J Trop Med Hyg. 2002 Dec;67(6):578-85
references.pmid: 12518847
references.citation: Am J Trop Med Hyg. 2006 Apr;74(4):546-53
references.pmid: 16606982
references.citation: Am J Trop Med Hyg. 2008 Jun;78(6):892-4
references.pmid: 18541765
references.citation: Am J Trop Med Hyg. 2003 May;68(5):608-12
references.pmid: 12812355
references.citation: Mem Inst Oswaldo Cruz. 2000 Sep-Oct;95(5):721-8
references.pmid: 10998224
references.citation: Am J Trop Med Hyg. 2003 Jan;68(1):120-3
references.pmid: 12557836
references.citation: Rev Soc Bras Med Trop. 2004 May-Jun;37(3):279-81
references.pmid: 15330070
references.citation: Am J Epidemiol. 2002 Aug 1;156(3):230-8
references.pmid: 12142257
references.citation: Trop Med Int Health. 2005 Nov;10(11):1176-9
references.pmid: 16262743
references.citation: Science. 2002 Apr 19;296(5567):545-7
references.pmid: 11964483
references.citation: Lancet. 1998 May 30;351(9116):1629-30
references.pmid: 9620719
references.citation: PLoS One. 2007 Jan 03;2(1):e139
references.pmid: 17206274
references.citation: Am J Trop Med Hyg. 1999 Nov;61(5):802-6
references.pmid: 10586915
references.citation: Antimicrob Agents Chemother. 2007 Jun;51(6):1926-33
references.pmid: 17371812
references.citation: Clin Pharmacol Ther. 2006 Dec;80(6):582-96
references.pmid: 17178260
references.citation: J Infect Dis. 2006 Apr 1;193(7):978-86
references.pmid: 16518760
references.citation: Am J Trop Med Hyg. 2003 Aug;69(2):174-8
references.pmid: 14506773
references.citation: Malar J. 2007 Jan 15;6:2
references.pmid: 17224049
references.citation: Am J Trop Med Hyg. 1995 Jun;52(6):565-8
references.pmid: 7611566
references.citation: Trans R Soc Trop Med Hyg. 2005 May;99(5):341-6
references.pmid: 15780340
references.citation: Am J Trop Med Hyg. 2005 Dec;73(6):1131-4
references.pmid: 16354825
references.citation: Parasitol Res. 2005 Oct;97(4):287-9
references.pmid: 16012864
references.citation: Malar J. 2005 Sep 15;4:42
references.pmid: 16164748
references.citation: Mol Biochem Parasitol. 1998 Aug 1;94(2):205-14
references.pmid: 9747971
references.citation: Antimicrob Agents Chemother. 1985 Apr;27(4):525-30
references.pmid: 3890727
references.citation: J Infect Dis. 1978 Feb;137(2):122-30
references.pmid: 627734
references.citation: Trends Parasitol. 2005 Jun;21(6):292-8
references.pmid: 15922251
references.citation: Trop Med Int Health. 2005 Oct;10(10):1030-7
references.pmid: 16185238
references.citation: J Infect Dis. 2006 Apr 15;193(8):1160-3
references.pmid: 16544257
references.citation: Am J Trop Med Hyg. 2006 Oct;75(4):640-4
references.pmid: 17038686
references.citation: Southeast Asian J Trop Med Public Health. 2001 Mar;32(1):64-9
references.pmid: 11485097
references.citation: J Infect Dis. 2002 Oct 1;186(7):999-1006
references.pmid: 12232841
references.citation: Mol Biol Evol. 2005 Sep;22(9):1834-44
references.pmid: 15917494
references.citation: Science. 2004 Aug 20;305(5687):1124
references.pmid: 15326348